Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | PRCP | P42785 | 2/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312033 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL15421539 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL8513805 | 1.00 | SMN1; SMN2 (0.70) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| Hydrochloric Acid SCHEMBL8470875 | 0.98 | SMN1; SMN2 (0.68) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL10775754 | 0.86 | OPRM1 (0.65) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL3431402 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL14591478 | 0.86 | SMN1; SMN2 (0.64) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL11563463 | 0.84 | OPRM1 (0.66) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL6388437 | 0.83 | PTPRA (0.55) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT | |
| SCHEMBL7288777 | 0.83 | PTPRA (0.55) | SMN1; SMN2PRCPSLC22A1OPRM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-112334465-B | Tricyclic substituted oxaspiro derivatives, preparation and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2024-01-04 | — | — | US | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210169892-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2021-06-10 | — | — | US | disclosed |
| CN-112334465-A | Tricyclic substituted oxaspiro derivatives, preparation method and medical application thereof | 上海海雁医药科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| CN-112218850-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2020223536-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| WO-2001010806-A2 | PROCESS FOR THE PREPARATION OF ACYLATED 1,3-DICARBONYL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| CN-1058265-C | Quinazoline derivatives | YUHAN CORP (KR) | 2000-11-08 | — | — | CN | disclosed |
| US-6100278-A | COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS | SANOFI-SYNTHELABO (FR) | 2000-08-08 | — | — | US | disclosed |
| US-6015812-A | N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity | SANOFI-SYNTHELABO (FR) | 2000-01-18 | — | — | US | disclosed |
| WO-1999064002-A1 | SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| CN-1207098-A | Amidine and isothiourea derivatives as nitric oxide synthase inhibitors | ASTRA AB (SE) | 1999-02-03 | — | — | CN | disclosed |
| US-5686458-A | Quinazoline deriviates for treating peptic ulcer | YUHAN CORPORATION (KR) | 1997-11-11 | — | — | US | disclosed |
| CN-1113912-A | Quinazoline derivatives | — | 1995-12-27 | — | — | CN | disclosed |
| EP-0677049-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION, LTD. (KR) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014795-A1 | QUINAZOLINE DERIVATIVES | YUHAN CORPORATION (KR) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SMN1; SMN2 2611/4885PRCP 4681/4885SLC22A1 3726/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SMN1; SMN2 2611/4885PRCP 4681/4885SLC22A1 3726/4885 |
| US-20210169892-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SMN1; SMN2 2611/4885PRCP 4681/4885SLC22A1 3726/4885 |
| US-20240000792-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | SMN1; SMN2 2611/4885PRCP 4681/4885SLC22A1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.